Embryonal Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Conditions: Rhabdomyosarcoma; Rhabdomyosarcoma- Alveolar; Rhabdomyosarcoma-Embryonal Interventions: Drug: Dasatinib; Drug: Ganitumab Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified January 25, 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2017 Category: Research Source Type: clinical trials
